Abstracts Archive - Page 2200 of 2607 - ACR Meeting Abstracts

Abstract Number: 513 • 2014 ACR/ARHP Annual Meeting
Analysis of Shoulder Joint Destruction in Rheumatoid Arthritis Patients Treated with Biologics
Yukio Yonemoto, Koichi Okamura, Tetsuya Kaneko, Chisa Okura and Kenji Takagishi, Department of Orthopaedic Surgery, Gunma University Graduate School of Medicine, Maebashi, Japan
Background/Purpose The assessment of joint destruction in rheumatoid arthritis (RA) patients being treated with biologics is normally mainly carried out for small joints. There are…
Abstract Number: 514 • 2014 ACR/ARHP Annual Meeting
Methotrexate Reduces the Frequency of Prediabetes in Patients with Rheumatoid Arthritis or Psoriatic Arthritis
Katja Perdan-Pirkmajer¹, Sergej Pirkmajer², Alojzija Hocevar¹, ŽIga Rotar¹, Natasa Gaspersic¹, Sonja Praprotnik¹, Matija Tomsic³ and Ales Ambrozic¹, ¹Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia, ²Institute of Pathophysiology, Faculty of Medicine Ljubljana, Ljubljana, Slovenia, ³Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia, Ljubljana, Slovenia
Background/Purpose Rheumatoid arthritis (RA) and psoriatic arthritis (PsA) are associated with an increased risk of diabetes mellitus (DM). Disease-modifying anti-rheumatic drugs, including methotrexate (MTX), may…
Abstract Number: 515 • 2014 ACR/ARHP Annual Meeting
Dosing of Intravenous Tocilizumab in a Real-World Setting—Analyses from a US RA Registry
Dimitrios A. Pappas¹, Ani John², Jeffrey R. Curtis³, George W. Reed^4,5, Chitra Karki⁶, Robert Magner⁵, Joel M. Kremer⁷, Ashwini Shewade² and Jeffrey D. Greenberg^6,8, ¹Columbia University, New York, NY, ²Genentech, Inc, South San Francisco, CA, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Corrona, LLC., Southborough, MA, ⁵University of Massachusetts Medical School, Worcester, MA, ⁶Corrona, LLC, Southborough, MA, ⁷Albany Medical College and The Center for Rheumatology, Albany, NY, ⁸NYU School of Medicine, New York, NY
Background/Purpose: In the US, the recommended starting dose of intravenous tocilizumab (TCZ) in combination with DMARDs or as monotherapy is 4 mg/kg every 4 weeks…
Abstract Number: 505 • 2014 ACR/ARHP Annual Meeting
A Structured Approach for Comparative Benefit-Risk Assessment of Rituximab for the Treatment of Rheumatoid Arthritis
Ani John¹, George Quartey¹, Patricia B. Lehane², Nicole Mairon³, Michael Schulte³, Ashwini Shewade¹, Carol Chung¹ and Dominic Borie¹, ¹Genentech, Inc, South San Francisco, CA, ²Roche Products Ltd, Welwyn Garden City, United Kingdom, ³F. Hoffmann-La Roche Ltd, Basel, Switzerland
Background/Purpose: Rituximab in combination with methotrexate (MTX) is indicated for the treatment of adult patients with moderate to severe active rheumatoid arthritis (RA) who have…
Abstract Number: 484 • 2014 ACR/ARHP Annual Meeting
Reactivation of Hepatitis B Virus in Patients with Rheumatoid Arthritis after Anti-TNF Therapy
Seung Min Jung¹, Hong Ki Min¹, Jung Hee Koh¹, Jin Young Kang¹, Jennifer Lee¹, Seung-Ki Kwok², Ji Hyeon Ju¹, Hyeok-Jae Ko³, Kyung-Su Park⁴, Ho-Youn Kim¹ and Sung-Hwan Park¹, ¹Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea, ²Division of Rheumatology, Department of Internal Medicine, St. Mary’s hospital, The Catholic University of Korea, Seoul, South Korea, ³Division of Rheumatology, Department of Internal Medicine, Daejeon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Daejeon, South Korea, ⁴Internal Medicine, St. Vincent Hospital, SuWon Gyeonggi-do, South Korea
Background/Purpose: Anti-TNF therapy was known to increase the risk of certain infection. There are only limited data about the reactivation of hepatitis B virus (HBV)…
Abstract Number: 485 • 2014 ACR/ARHP Annual Meeting
Incidence of Clinical and Serological Lupus-like Disease during Anti-Tnfα-Treatment – a Two-Year Prospective Study in an Interdisciplinary Patient Cohort
Simon Julius Winkelmann¹, Rainald A. Zeuner¹, Dörte Schuldt¹, Johannes Bethge¹, Ulrich Mrowietz², Matthias Laudes¹, Stefan Schreiber¹ and Johann Schroeder¹, ¹1st Medical Dept, University of Kiel, Kiel, Germany, ²Dermatology, Univ Schleswig-Holstein, Kiel, Germany
Background/Purpose: TNFα-Inhibitors are the most widely used biological agents in rheumatic conditions or other chronic inflammatory diseases. Over the last ten years, the occurrence of…
Abstract Number: 483 • 2014 ACR/ARHP Annual Meeting
Risk of HBV Reactivation in Rheumatoid Arthritis Patients Undergoing Treatment with Newer Biological Dmards, Tocilizumab and Abatacept: A Single-Center Real Life Experience
Francesca De Nard¹, Vittorio Grosso², Monica Todoerti³, Carlomaurizio Montecucco⁴ and Roberto Caporali⁵, ¹Division of Rheumatology, University of Pavia, IRCCS Policlinico S. Matteo Foundation, Pavia, Italy, ²Division of Rheumatology, University of Pavia, Foundation IRCCS Policlinico S. Matteo, Pavia, Italy, ³Rheumatology, University of Pavia, IRCCS Policlinico S. Matteo Foundation, Pavia, Italy, ⁴Rheumatology and Translational Immunology Research Laboratories (LaRIT), Division of Rheumatology, IRCCS Policlinico S.Matteo Foundation/University of Pavia, Pavia, Italy, ⁵Division of Rheumatology, Rheumatology and Translational Immunology Research Laboratories (LaRIT), Division of Rheumatology, IRCCS Policlinico S.Matteo Foundation/University of Pavia, Pavia, Italy
Background/Purpose HBV infection represents a major issue in patients with rheumatoid arthritis (RA) undergoing biological disease-modifying anti-rheumatic drugs (bDMARDs) (1). While the risk of hepatitis…
Abstract Number: 482 • 2014 ACR/ARHP Annual Meeting
Incidence of Opportunistic Infections in Rheumatoid Arthritis Treated with Biological Agents
Alejandro Gomez-Gomez^1,2, Zulema Rosales^1,2, Leticia Leon², Juan A Jover², Luis Rodriguez-Rodriguez² and Lydia Abasolo², ¹Rheumatology, Hospital Clinico San Carlos, Madrid, Spain, ²Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain
Background/Purpose With the expanding use of Biological Agents (BA), in particular TNF inhibitors, opportunistic infections (OI) are a major concern in Rheumatology. Our purposes were…
Abstract Number: 481 • 2014 ACR/ARHP Annual Meeting
Efficacy and Safety of Etanercept in Rheumatoid Arthritis Patients over 75 Years Old
Satoru Kodama, Satoshi Ito, Akira Murasawa, Kiyoshi Nakazono and Daisuke Kobayashi, Niigata Rheumatic Center, Shibata, Japan
Background/Purpose Early introductions of biologics in early rheumatoid arthritis (RA) patients are well documented, but there are few reports of biologics use in established elderly…
Abstract Number: 480 • 2014 ACR/ARHP Annual Meeting
Serious Infection Risk By Treatments and Types in Patients with RA
Kaleb Michaud^1,2, Sofia Pedro¹, Andre Kalil³, Ted R. Mikuls⁴ and Frederick Wolfe¹, ¹National Data Bank for Rheumatic Diseases, Wichita, KS, ²Internal Medicine, University of Nebraska Medical Center, Omaha, NE, ³Infectious Diseases, University of Nebraska Medical Center, Omaha, NE, ⁴University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Recent studies provide conflicting results on the impact of DMARDs on the risk of serious infections for patients with RA. We examined these infection…
Abstract Number: 479 • 2014 ACR/ARHP Annual Meeting
Long Term Safety of Intravenous Golimumab and Comparison with Subcutaneous Golimumab in Rheumatoid Arthritis: Results through 2 Years
Rene Westhovens¹, Edward C. Keystone², Clifton O. Bingham III³, Elizabeth C. Hsia^4,5, Lilianne Kim⁴, Yiying Zhou⁴, Alan M. Mendelsohn⁶ and Michael E. Weinblatt⁷, ¹Rheumatology, University Hospital KU Leuven, Leuven, Belgium, ²Department of Medicine, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ³Johns Hopkins University, Baltimore, MD, ⁴Janssen Research & Development, LLC., Spring House, PA, ⁵University of Pennsylvania, Philadelphia, PA, ⁶Immunology, Janssen Research & Development, LLC., Spring House, PA, ⁷Division of Rheumatology & Immunology, Brigham and Women's Hospital, Boston, MA
Long Term Safety of Intravenous Golimumab and Comparison with Subcutaneous Golimumab in Rheumatoid Arthritis: Results through 2 Years Background/Purpose: To describe the safety profile…
Abstract Number: 498 • 2014 ACR/ARHP Annual Meeting
Patient Experience with Initiation of SQ and Oral MTX
Jeffrey R. Curtis¹, David Mackey², Noam Gerber³, Aseem Bharat¹, Lang Chen⁴, Fenglong Xie⁵, Ben Nowell³, Kenneth G. Saag⁶ and Seth Ginsberg⁷, ¹University of Alabama at Birmingham, Birmingham, AL, ²Clinical Immunology/Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Creaky Joints/Global Healthy Living Foundation, Upper Nyack, NY, ⁴Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁵Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, ⁶Immunology & Rheumatology, The University of Alabama at Birmingham, Birmingham, AL, ⁷CreakyJoints/Global Healthy Living Foundation, Upper Nyack, NY
Background/Purpose Methotrexate is the anchor drug used for the treatment of rheumatoid arthritis (RA). Despite its prominent position in RA therapeutics, its real-world effectiveness may…
Abstract Number: 497 • 2014 ACR/ARHP Annual Meeting
Efficacy and Safety Study of a Sequential Therapy of Tocilizumab and, If Initially Inadequately Responded to Tocilizumab, Followed By Rituximab in Patients with Rheumatoid Arthritis and Inadequate Response to Traditional Disease Modifying Anti-Rheumatic Drugs
Thomas Dörner¹, Hans-Peter Tony², Gerd Burmester¹, Hendrik Schulze-Koops³, Jörg Kaufmann⁴, Peter Kästner⁵, Herbert Kellner⁶, Reiner Kurthen⁷, Sylke Wagner⁸, Marvin A. Peters⁹ and Christoph Iking-Konert¹⁰, ¹Charité - Universitätsmedizin Berlin, Berlin, Germany, ²University Clinic Wuerzburg, Wuerzburg, Germany, ³University Clinic Munich, Munich, Germany, ⁴Rheumatology Practice, Ludwigsfelde, Germany, ⁵MVZ Out-patient Rheumatogy Unit Erfurt, Erfurt, Germany, ⁶Specialist Practice for Rheumatology and Gastroenterology, Munich, Germany, ⁷Rheumatology Practice, Aachen, Germany, ⁸Practice for Internal Medicine specialized in Rheumatology, Halle, Germany, ⁹Roche Pharma AG, Grenzach-Wyhlen, Germany, ¹⁰University Clinic Hamburg-Eppendorf, Hamburg, Germany
Background/Purpose: The MIRAI study evaluated a sequential exposure to 2 defined biologics under rigorous study conditions within a homogeneous population of biological naïve patients (pts)…
Abstract Number: 496 • 2014 ACR/ARHP Annual Meeting
Efficacy and Safety of Induction Therapy for Rheumatoid Arthritis with Simultaneous Administration of Methotrexate and Low-Dose Tacrolimus: A Retrospective Study
Takashi Nakanishi¹, Hideyuki Horikoshi¹, Reiko Takahashi¹, Kanami Tongu², Junko Nishioka², Fumihiko Kimura³, Yuichi Nishioka² and Kenji Itoh¹, ¹Division of Rheumatology, Department of Internal Medicine, National Defense Medical College, Tokorozawa, Japan, ²Nishioka Clinic for Rheumatic Diseases and Allergic Diseases, Kofu, Japan, ³National Defense Medical College, Tokorozawa, Japan
Background/Purpose Additional administration of low-dose tacrolimus (LD-TAC) at 0.5–1.0 mg daily was reported to be quite effective for rheumatoid arthritis (RA) patients with inadequate response…
Abstract Number: 495 • 2014 ACR/ARHP Annual Meeting
Discontinuation of Biologics in Patients with Rheumatoid Arthritis after Achieving Low-Activity Disease Status
Moeko Ochiai¹, Eri Sato¹, Eiichi Tanaka¹, Eisuke Inoue¹, Ayako Nakajima¹, Shigeki Momohara², Atsuo Taniguchi² and Hisashi Yamanaka², ¹Rheumatology, Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan, ²Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan
Background/Purpose: Several clinical trials have reported bio-free remission or discontinuation of biologic DMARDs; however, these findings have not been confirmed in a real-world setting. The…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].